Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era

[1] Leiter U(2016)Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial Lancet Oncol. 17 757-767

[2] Stadler R(2019)Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node J Clin Oncol. 37 3000-3008

[3] Mauch C(2017)Completion dissection or observation for sentinel-node metastasis in melanoma N Engl J Med. 376 2211-2222

[4] Leiter U(2017)Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N Engl J Med. 377 1824-1835

[5] Stadler R(2018)Adjuvant pembrolizumab versus placebo in resected stage iii melanoma N Engl J Med. 378 1789-1801

[6] Mauch C(2017)Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma N Engl J Med. 377 1813-1823

[7] Faries MB(2020)Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up J Clin Oncol. 25 356-377

[8] Thompson JF(2019)A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy JCO 29 2199-2205

[9] Cochran AJ(2018)Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update Ann Surg Oncol. 107 1480-1488

[10] Weber J(2011)Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database J Clin Oncol. 27 5121-5125

[1] Leiter U(2016)Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial Lancet Oncol. 17 757-767

[2] Stadler R(2019)Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node J Clin Oncol. 37 3000-3008

[3] Mauch C(2017)Completion dissection or observation for sentinel-node metastasis in melanoma N Engl J Med. 376 2211-2222

[4] Leiter U(2017)Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N Engl J Med. 377 1824-1835

[5] Stadler R(2018)Adjuvant pembrolizumab versus placebo in resected stage iii melanoma N Engl J Med. 378 1789-1801

[6] Mauch C(2017)Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma N Engl J Med. 377 1813-1823

[7] Faries MB(2020)Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up J Clin Oncol. 25 356-377

[8] Thompson JF(2019)A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy JCO 29 2199-2205

[9] Cochran AJ(2018)Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update Ann Surg Oncol. 107 1480-1488

[10] Weber J(2011)Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database J Clin Oncol. 27 5121-5125